Skip to main content
Fig. 2 | Experimental Hematology & Oncology

Fig. 2

From: Changes in clinical laboratory parameters and pharmacodynamic markers in response to blinatumomab treatment of patients with relapsed/refractory ALL

Fig. 2

Blinatumomab-induced changes in peripheral blood cell subpopulations. Redistribution of neutrophils (a) and thrombocytes (b), expansion of T cells (c), and kinetics of B-cell depletion (d) in responders versus nonresponders during treatment cycle 1 and 2. Patients were stratified into responders (blue) and nonresponders (red) based on CR/CRh response during the first two treatment cycles. Box plots depict cell counts of all evaluable patients during cycles 1 and 2. Black line median counts; plus sign mean counts; circle outlying value. Boxes extend from the 25th to 75th percentile, with bars extending to the minimum and maximum values within 1.5 times the interquartile range (difference between the 25th and 75th percentile). Corresponding patient numbers are shown in Additional file 2

Back to article page